文献速递腹部介入MR

利用MRI定量肿瘤负荷影像生物标志物优化BCLC分期系统以指导肝细胞癌局部治疗

Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
PubMed 文献 · Radiology · 2022-04-12

本回顾性研究纳入682例接受传统TACE或药物洗脱微球TACE的肝细胞癌患者,通过对比增强MRI三维定量分析确定强化肿瘤体积(ETV)和强化肿瘤负荷(ETB)阈值,将ETV低于65 cm³或ETB低于4%的中期和晚期患者重新归类为BCLC Bn,其余归为BCLC Cn,两组中位总生存期分别为25.1个月和8.4个月。

要点

  • ETV≥65 cm³或ETB≥4%的BCLC C期患者中位总生存期仅8.4个月。
  • ETV<65 cm³或ETB<4%的BCLC C期患者重分类为BCLC Bn后中位总生存期达25.1个月。
  • 治疗前MRI三维定量肿瘤负荷可用于优化BCLC分期并筛选TACE获益人群。

核心结论

  • 根据三维定量肿瘤负荷对中期和晚期肝细胞癌患者进行亚分层,可识别出从TACE治疗中获益的患者。

研究设计与样本

  • 回顾性研究,纳入2000年1月至2014年12月接受传统TACE或药物洗脱微球TACE的682例肝细胞癌患者,最终分析494例(中位年龄62岁,IQR 56-71岁;401例男性),采用对比增强MRI三维定量分析确定ETV和ETB阈值。

诊断标准与关键数值

  • ETV低于65 cm³或ETB低于4%者重新归类为BCLC Bn;ETV≥65 cm³或ETB≥4%者归为BCLC Cn。

临床应用与阅片要点

  • 治疗前可基于对比增强MRI三维定量测量ETV和ETB,按65 cm³和4%阈值对中期和晚期肝细胞癌进行亚分层,以辅助筛选适合TACE的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Patients with intermediate- and advanced-stage hepatocellular carcinoma (HCC) represent a highly heterogeneous patient collective with substantial differences in overall survival. Purpose To evaluate enhancing tumor volume (ETV) and enhancing tumor burden (ETB) as new criteria within the Barcelona Clinic Liver Cancer (BCLC) staging system for optimized allocation of patients with intermediate- and advanced-stage HCC to undergo transarterial chemoembolization (TACE). Materials and Methods In this retrospective study, 682 patients with HCC who underwent conventional TACE or TACE with drug-eluting beads from January 2000 to December 2014 were evaluated. Quantitative three-dimensional analysis of contrast-enhanced MRI was performed to determine thresholds of ETV and ETB (ratio of ETV to normal liver volume). Patients with ETV below 65 cm3 or ETB below 4% were reassigned to BCLC Bn, whereas patients with ETV or ETB above the determined cutoffs were restratified or remained in BCLC Cn by means of stepwise verification of the median overall survival (mOS). Results This study included 494 patients (median age, 62 years [IQR, 56-71 years]; 401 men). Originally, 123 patients were classified as BCLC B with mOS of 24.3 months (95% CI: 21.4, 32.9) and 371 patients as BCLC C with mOS of 11.9 months (95% CI: 10.5, 14.8). The mOS of all included patients (including the BCLC B and C groups) was 15 months (95% CI: 12.3, 17.2). A total of 152 patients with BCLC C tumors were restratified into a new BCLC Bn class, in which the mOS was then 25.1 months (95% CI: 21.8, 29.7; P < .001). The mOS of the remaining patients (ie, BCLC Cn group) (n = 222; ETV ≥65 cm3 or ETB ≥4%) was 8.4 months (95% CI: 6.1, 11.2). Conclusion Substratification of patients with intermediate- and advanced-stage hepatocellular carcinoma according to three-dimensional quantitative tumor burden identified patients with a survival benefit from transarterial chemoembolization before therapy. © RSNA, 2022 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Borde, Nezami, Laage Gaupp, et al. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology. 2022. PMID: 35412368. doi:10.1148/radiol.212426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。